Year All2026202520242023202220212020 Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results June 29, 2026 Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering June 25, 2026 Helus Pharma™ Announces US$50 Million Underwritten Offering June 24, 2026 Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress June 24, 2026 Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference June 11, 2026 Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York June 1, 2026 Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference April 30, 2026 Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health April 28, 2026 Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan April 23, 2026 Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions April 20, 2026
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference June 11, 2026
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan April 23, 2026
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions April 20, 2026
